Table 1.

Patient baseline demographics; safety set

	Dose-titration phase (n= 39)	Parallel-group phase
		Lanthanum carbonate (n= 10)	Placebo (n= 11)
Sex, n (%)
Male	30 (76.9)	6 (60.0)	8 (72.7)
Female	9 (23.1)	4 (40.0)	3 (27.3)
Ethnicity, n (%)
Asian	1 (2.6)	0 (0.0)	0 (0.0)
Caucasian	38 (97.4)	10 (100.0)	11 (100.0)
Age, yearsa	53.4 (15.6)	51.5 (17.5)	54.4 (15.3)
Duration of renal disease, yearsb	5.0 (1.0-41.0)	4.0 (1.0-21.0)	9.0 (1.0-41.0)
Duration of dialysis, monthsb	17.0 (6.0-107.0)	11.0 (6.0-87.0)	13.0 (6.0-107.0)
Previous transplant, n (%)	8 (20.5)	2 (20.0)	3 (27.3)

^aMean (standard deviation).

^bMedian (minimum, maximum).